Teva reports Q4 non-GAAP EPS 96c, consensus 64c

Reports Q4 revenue $4.7B, consensus $4.33B. Richard Francis, Teva‘s (TEVA) President and CEO, said: “In 2025, our Pivot to Growth strategy drove Teva’s third year of consecutive growth, solidifying our transformation into a leading biopharmaceutical company. Our key innovative brands led our growth, reaching $1B in revenues in the fourth quarter of 2025 for the first time, and becoming a true engine of sustainable growth. Throughout the year, our teams executed with discipline across the business, driving momentum in innovative medicines, scaling our global generics and biosimilars portfolio, and further optimizing our operations and capital allocation. We also continue to make progress on our deleveraging, in line with our 2027 targets.”